ADH-6 |
カタログ番号GC64235 |
ADH-6はトリピリジルアミド化合物です。 ADH-6 は、変異型 p53 DBD の凝集核形成サブドメインの自己組織化を無効にします。 ADH-6 は、ヒト癌細胞の変異型 p53 凝集体を標的にして解離し、p53 の転写活性を回復させ、細胞周期の停止とアポトーシスを引き起こします。 ADH-6 は、がん疾患の研究に役立つ可能性があります 。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2227429-65-2
Sample solution is provided at 25 µL, 10mM.
ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53’s transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
[1]. Palanikumar L, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12(1):3962.
Average Rating: 5
(Based on Reviews and 38 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *